Related Experiment Video
Updated: Jun 27, 2026
09:58
RhoC GTPase Activation Assay
Published on: August 22, 2010
Progression of breast tumors is accompanied by a decrease in expression of the Rho guanine exchange factor Tiam1.
A Stebel1, C Brachetti, M Kunkel
1Department of Toxicology, University of Mainz, D-55131 Mainz, Germany.
Oncology Reports
|December 17, 2008
Summary
T-cell lymphoma invasion and metastasis 1 (Tiam1) expression decreases in advanced breast cancer. Low Tiam1 levels correlate with tumor progression, suggesting Tiam1 as a potential biomarker for breast carcinoma.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Ras-homologous (Rho) GTPases are key regulators of cell motility and invasion.
- T-cell lymphoma invasion and metastasis 1 (Tiam1) is a specific guanine nucleotide exchange factor (GEF) for Rac1, a Rho GTPase.
- Aberrant Rho GTPase signaling is implicated in various cancers, including breast carcinoma.
Purpose of the Study:
- To investigate the expression levels of Rho GTPases and Tiam1 in breast tumor specimens.
- To correlate Rho and Tiam1 expression with established diagnostic and prognostic parameters of breast cancer.
- To evaluate the potential of Tiam1 as a novel biomarker for breast carcinoma progression.
Main Methods:
- Immunohistochemistry was employed to assess Rho GTPase and Tiam1 expression in 106 breast tumor specimens.
- Expression scores were quantitatively analyzed and compared with clinical parameters such as tumor grade, spreading, proliferation, and receptor status (ER, PR, HER2/neu).
- Statistical analysis was performed to determine correlations between Tiam1 expression and various clinicopathological features, including p53 and PAI-1 status.
Main Results:
- RhoA and RhoB expression showed a slight increase with higher tumor grade, while Rac1 expression remained unchanged.
- Tiam1 expression significantly decreased with increasing tumor grade, tumor spreading, and proliferation.
- Tiam1 expression was inversely correlated with plasminogen activator inhibitor (PAI-1) and estrogen receptor (ER) status, and associated with p53 positivity, but not with PR or HER2/neu status.
Conclusions:
- Tiam1 expression diminishes as breast carcinomas progress, indicating a role in counteracting tumor advancement.
- The inverse association of Tiam1 with tumor progression markers suggests its potential as a novel prognostic biomarker for breast cancer.
- Further research into Tiam1's functional role in breast cancer pathogenesis is warranted.
More Related Videos
08:48An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
Published on: June 30, 2015
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Related Concept Videos
01:24Small GTPases - Ras and Rho
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...